Baxter Changes Reportable Segments To Two Segments Effective Q2 2026 - SEC Filing - BAX News | RalliesBaxter Changes Reportable Segments To Two Segments Effective Q2 2026 - SEC Filing
B
BAX• Baxter to report two segments starting in Q2 2026
- Baxter changes reportable segments to two segments effective Q2 2026, according to an SEC filing.
- The pharmaceuticals segment will now be reported within the Infusion Therapies & Platforms division.
- Shared corporate expenses will remain unallocated in segment reporting.
- Baxter said the changes do not impact its previously issued consolidated financial statements except for segment disclosures.
•
